BVS · Bioventus
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $13.15
Note written ·
Price against the kill line
18.9% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $13.15, on record since 11 November 2026. The shares are down 23.2% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $13.15, the close before the 2 November 2026 results, which would show the shares leading the S&P 500 again; an announced sale agreement would also show the call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 26 September 2026, filed 2 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 142
- Revenue, change on a year (%)
- +2.7
- Gross margin (%)
- 68.2
- Operating margin (%)
- 6.8
- Free cash flow, four quarters ($M)
- 85.0
- Net cash, cash less debt ($M)
- −199
- Price to earnings (×)
- 13.5
- Enterprise value to sales (×)
- 1.7
All filed numbers
What Bioventus reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 142 | +2.7 | 68.2 | 6.8 |
| first filed | 153 | +3.8 | 69.0 | 12.5 |
| first filed | 132 | +6.6 | 68.7 | 6.4 |
| first filed | 158 | +2.8 | 68.9 | 12.3 |
| first filed | 139 | −0.2 | 68.0 | 8.1 |
| first filed | 148 | −2.4 | 69.1 | 12.4 |
| Pre-tax income ($M) | 6.2 |
| Net income ($M) four quarters: 57.3 | 6.0 |
| Diluted shares, change on a year (%) against the quarter to 27 September 2025 | +5.3 |
| Operating cash flow ($M) | 87.4 |
| Capital spending ($M) | 2.4 |
| Free cash flow ($M) | 85.0 |
| Cash and short-term investments ($M) | 30.7 |
| Debt ($M) non-current long-term debt plus current maturities | 230 |
| Net cash, cash less debt ($M) | −199 |
| Deferred revenue ($M) at 31 December 2025, filed 5 March 2026; −43.1% on a year | 1.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 138 |
| Inventory ($M) | 83.1 |
| Shareholders' equity ($M) | 241 |
| Market value ($M) | 773 |
| Enterprise value, market value plus net debt ($M) | 972 |
| Enterprise value to sales (×) | 1.7 |
| Enterprise value to operating income (×) | 17.1 |
| Price to earnings (×) | 13.5 |
| Price to book value (×) | 3.2 |
| Free-cash-flow yield (%) | 11.0 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 4.4% of shares outstanding sold short, 8.9 days of average trading to cover, +0.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $181K |
The thesis
Bioventus's shares are more likely to lag the S&P 500 over the next three months, because the case rests on a strategic review ending in a sale and the standalone business just lowered its sales outlook. A signed sale agreement with a disclosed price, or a statement that the review ended without one, settles it.
Bioventus disclosed the review on 5 August 2026, after an unsolicited acquisition proposal and other expressions of interest. In its 2 November 2026 third-quarter report the company said it "continues to review potential strategic alternatives", and management declined to take questions about it on the call. Cash paid for the review was $0.4 million in the third quarter and in the nine months to 26 September 2026 (8-K exhibit, 2 November 2026).
The shares closed at $10.99 on 11 November 2026. That is 20.9% below the adjusted close of 13 August 2026 ($13.89, the three-month reference) and 30.8% below the 52-week intraday high of $15.89 set on 5 August 2026, the day the review was disclosed. In this view, the price now carries little of the deal premium of August and early autumn.
Bullish and bearish views on Bioventus Inc.
The bull case on Bioventus Inc. (BVS), in brief: a sale process remains open. The bear case: sales guidance was cut.
Bull case
- A sale process remains open. The 2 November 2026 release repeated that the review continues. No offer price has been disclosed, so any agreement would be the first price evidence.
- Earnings guidance held. Bioventus reaffirmed 2026 adjusted earnings of $0.75 to $0.79 per share on 2 November 2026. Third-quarter adjusted earnings of $0.17 per share beat the $0.16 estimate (Benzinga, 2 November 2026).
- Pain Treatments and international sales grew. Pain Treatments revenue was $71.3 million, up 6.2%. International sales were $17.8 million, up 16.4% (8-K exhibit, 2 November 2026).
- Debt keeps falling. Third-quarter cash from operations was $20.7 million, and Bioventus prepaid $15.0 million of its term loan. Cash was $30.7 million on 26 September 2026 (8-K exhibit, 2 November 2026).
- Analysts remain positive. Canaccord Genuity maintained its Buy rating and lowered its price target to $18 (company news, 4 November 2026).
Bear case
- Sales guidance was cut. On 2 November 2026 Bioventus lowered 2026 net-sales guidance to $590 million–$595 million from $600 million–$610 million.
- Third-quarter sales missed. Net sales were $142.442 million against a $149.461 million estimate (Benzinga, 2 November 2026). Reported sales rose 2.7%.
- Two segments were flat or falling. Surgical Solutions revenue was $50.5 million, up 0.7%, on softer bone graft substitutes. Restorative Therapies was $20.6 million, down 3.4% (8-K exhibit, 2 November 2026).
- The review may end without a sale. Bioventus said on 5 August 2026 that the review has no timetable and may end without a transaction. A standalone company with a lowered sales outlook leaves less to support the price.
- Cash balance declined. Cash was $30.7 million on 26 September 2026, against $51.2 million on 31 December 2025 (8-K exhibit, 2 November 2026).
Price setup
The shares closed at $10.99 on 11 November 2026, a hair below the 200-day average of $11.03 and well below the 50-day average of $13.28 (adjusted daily closes). The three-month change was −20.9%. The shares closed at $11.42 on 4 November 2026 and $10.61 on 6 November 2026, then held between $10.99 and $11.18 in the sessions of 9 November to 11 November 2026.
The 52-week intraday high is $15.89 (5 August 2026) and the 52-week closing low is $6.53 (20 November 2025). The 50-day average sitting above the last close shows how much of the autumn gain has been given back since the guidance cut.
No insider transactions appear in the SEC filings listed for the shares; the only recent filing is the 10-Q of 2 November 2026. The next reported results fall outside the next 30 days. Until then, price moves depend on review news the company has said it will disclose only if the board approves a transaction or disclosure is required.
Catalysts ahead
- Undated: Any announcement on the strategic review outcome. A sale agreement with a disclosed price, or a statement that the review ended without one, settles the main case.
- ~1 March 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether 2026 net sales landed inside the lowered $590 million–$595 million range.
What would change the view
A daily close above $13.15, the close before the 2 November 2026 results, which would show the shares leading the S&P 500 again; an announced sale agreement would also show the call wrong.
What it trades with
Bioventus trades on deal expectation and its own sales results, so its link to broad indexes is loose. Its Pain Treatments segment depends on reimbursement and coverage for hyaluronic acid therapies, which Bioventus named as a risk in its 5 August 2026 release. Moves in other small-cap medical-device shares matter less than the review's outcome.
The evidence, claim by claim (7)
- Third-quarter 2026 net sales were $142.4 million, up 2.7%; Pain Treatments $71.3 million (+6.2%), Surgical Solutions $50.5 million (+0.7%), Restorative Therapies $20.6 million (−3.4%). Bioventus 8-K Exhibit 99.1, third-quarter 2026 release · as of
- Bioventus lowered 2026 net-sales guidance to $590 million–$595 million from $600 million–$610 million and reaffirmed adjusted EPS of $0.75–$0.79. Bioventus release; Benzinga · as of
- Third-quarter sales of $142.442 million missed a $149.461 million estimate; adjusted EPS of $0.17 beat a $0.16 estimate. Benzinga · as of
- Bioventus said it continues to review potential strategic alternatives; review cash costs were $0.4 million in the quarter and nine months. Bioventus 8-K Exhibit 99.1 · as of
- Third-quarter cash from operations was $20.7 million; a $15.0 million term-loan prepayment was made; cash was $30.7 million on 26 September 2026. Bioventus 8-K Exhibit 99.1 · as of
- Canaccord Genuity maintained Buy and lowered its price target to $18. Company news headlines · as of
- Shares closed at $10.99, 30.8% below the 52-week intraday high of $15.89 set on 5 August 2026; three-month change −20.9%. Adjusted daily closes · as of
Sources
- Bioventus Inc. - Form 8-K - FY2026 · sec.gov
- MarketBeat ·
- Bioventus Q3 revenue rises 3% but misses estimates · capital.com
- BioSpace
Related · shared themes
CDNA
CareDx
CareDx's shares are modestly more likely than not to beat the S&P 500: transplant testing revenue grew 39% in the third quarter excluding…
GRAL
GRAIL
GRAIL's shares are more likely to lag the S&P 500 over three months: after a 78.8% three-month rise, approval of the Galleri cancer test…
QDEL
QuidelOrtho
QuidelOrtho's shares are more likely to lag the S&P 500: third-quarter revenue fell 11.6% and net leverage rose to 4.5 times while the…
PLSE
Pulse Biosciences
Pulse Biosciences is modestly more likely to lead the S&P 500 because $189.2 million of cash funds its atrial-fibrillation catheter through…
See also · stocks to watch